Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse Cardiac Catheter System at Heart Rhythm 2026
Pulse Biosciences announced positive clinical data from their nPulse Cardiac Catheter System during the Heart Rhythm 2026 conference. The data presented were part of a first-in-human feasibility study and included follow-up information from participants.
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking positive clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. The late-breaking presentation included incremental participant follow up data. Building upon the previously reported data set presented at